Form 4 Absci Corp For: 6 July By Investing.com
The article reports on a Form 4 filing for Absci Corp, dated July 6, according to Investing.com. It is a brief announcement without further details on the filing's content. The main body of the article appears to be mostly navigation and stock market data, unrelated to the specific Form 4 filing.
Absci director Mary T Szela buys $148,866 in stock By Investing.com
Absci Corp. director Mary T Szela recently purchased 12,900 shares of company stock for $148,866, bringing her total direct ownership to 21,300 shares. This insider buying activity occurs as the stock trades near its 52-week high and has delivered a significant return over the past year, though InvestingPro analysis suggests it may be overvalued. The company also reported positive interim results for its ABS-201 study and announced a $100 million stock offering to fund drug programs.
Absci (ABSI) director buys 12,900 shares in open-market trade
Absci Corp. director Mary T. Szela purchased 12,900 shares of Common Stock at $11.54 per share on June 30, 2026, in an open-market transaction. This transaction increased her direct ownership to 21,300 shares, as detailed in the SEC Form 4 filing. The purchase was executed in accordance with the issuer's trading policies, signaling a positive sentiment from the insider.
Enterprise value to revenue forward of Absci Corporation – NASDAQ:ABSI
This article provides the enterprise value to revenue (forward) for Absci Corporation (NASDAQ: ABSI). It specifies the period, the value, and the percentage change for this financial metric. The information is presented by TradingView, sourcing data from ICE Data Services and FactSet.
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $17
Truist Financial has reiterated its "Buy" rating for Absci Corp (ABSI.US) and increased its target price to $17. This indicates a positive outlook from the financial institution regarding Absci's stock performance.
Price to sales forward of Absci Corporation – NASDAQ:ABSI
This article provides a view of Absci Corporation's (NASDAQ: ABSI) financial data, specifically focusing on its forward price-to-sales ratio. It briefly lists essential financial and market information available on TradingView for the company. The content appears to be a stub or a section focused on a specific financial metric for the biotechnology company.
BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13
BTIG has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained its target price at $13. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
ABSI Maintained by Truist Securities -- Price Target Raised to $17.00
Truist Securities has maintained a Buy rating for Absci (ABSI) and increased its price target from $11.00 to $17.00, indicating a bullish outlook. Despite this, GuruFocus assesses ABSI as significantly overvalued by 527.4% with a GF Value of $1.77 against its current price of $11.11, while its GF Score of 57/100 points to moderate performance potential. Insider buying activity of $200,748 over the last three months suggests confidence from within the company.
Absci (ABSI) Is Up 10.3% After Positive ABS-201 Phase 1 Data And $100M Equity Raise
Absci Corporation's stock (ABSI) rose 10.3% following positive interim Phase 1 data for its ABS-201 drug, which targets androgenetic alopecia, demonstrating favorable safety and a long half-life. Concurrently, the company completed a $100 million equity offering, providing capital to advance ABS-201 through upcoming proof-of-concept milestones. This development highlights Absci's strategy to differentiate itself in the hair loss market and mitigate risks associated with its ongoing losses and reliance on a single biologic.
Enterprise value to EBITDA forward of Absci Corporation – NASDAQ:ABSI
This article provides access to the enterprise value to EBITDA forward metric for Absci Corporation (NASDAQ:ABSI) through TradingView. It indicates that the market for ABSI was closed at the time of viewing, with no trades mentioned. The content primarily focuses on navigation and other features available on the TradingView platform related to financial data and analysis for stocks.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright has reiterated its Buy rating on Absci Corp (ABSI.US), keeping its target price at $16. This indicates the firm's continued confidence in the company's stock performance.
Price to earnings forward of Absci Corporation – NASDAQ:ABSI
This article provides price-to-earnings forward data for Absci Corporation (NASDAQ: ABSI). It presents a table showing the period, value, and change percentage for this financial metric. The content is hosted on TradingView, indicating that it is a financial data point for investors tracking the company's performance.
Absci Corporation Actuals & Estimates (NASDAQ:ABSI)
This article provides an overview of Absci Corporation (NASDAQ: ABSI) stock performance, financial actuals, and analyst estimates. It highlights recent stock price movements, market capitalization, future price forecasts, and key financial metrics including earnings, revenue, and EBITDA. The company does not currently pay dividends and its next earnings report is expected on August 18, 2026.
Absci Stock (ABSI) Opinions on Positive Phase 1 Data for ABS-201
Absci Corporation recently announced positive Phase 1 clinical trial data for its lead AI-generated de novo therapeutic candidate, ABS-201, designed for ulcerative colitis. The trial results showed ABS-201 was well-tolerated with dose-proportional pharmacokinetics and minimal anti-drug antibodies, supporting its advancement to Phase 2. This represents a significant milestone for Absci's AI drug discovery platform and highlights the potential of generative AI in developing novel biologics.
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $11 to $16
This article provides an overview of recent analyst ratings for Absci Corp (ABSI.US), indicating a positive sentiment with 10 analysts issuing bullish estimates. The price target ranges from $11 to $16, with an average of $13.6, suggesting a significant potential upside from its current trading price. The ratings are based on a combination of technical and fundamental analysis.
Absci (Nasdaq: ABSI) shows favorable Phase 1 ABS-201 safety profile
Absci Corporation reported positive interim Phase 1 results for its drug candidate ABS-201, designed for androgenetic alopecia, from the HEADLINE trial. The drug demonstrated a favorable safety profile across all single ascending dose cohorts with no serious adverse events and an estimated half-life of at least 65 days, supporting a potential infrequent dosing schedule. The study has advanced to multiple ascending dose trials, with proof-of-concept data expected in late 2026 and early 2027.
Absci (NASDAQ: ABSI) CEO has 59,896 shares withheld for RSU tax obligation
Absci Corp's CEO, Sean McClain, reported a tax-related share disposition. On June 24, 2026, 59,896 shares of common stock were withheld by the company at $10.075 per share to cover tax obligations from the vesting of 150,000 performance-based Restricted Stock Units (RSUs). This vesting was triggered by Absci's stock price reaching $10.00, and after the withholding, McClain directly holds 8,655,555 shares.
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Absci Corporation has raised $100 million in an underwritten offering, with significant investment from Eli Lilly and BVF Partners, to advance its lead AI-designed antibody, ABS-201. The funds will primarily support a global Phase II study for endometriosis by late 2026 and potentially a Phase III study for male pattern hair loss in late 2027, following promising Phase I safety data. ABS-201 targets the anti-prolactin receptor and shows potential for long-lasting effects with a favorable safety profile compared to existing treatments.
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Absci Corporation has secured $100 million in an underwritten offering, with investments from prominent bidders like Eli Lilly, to advance its lead artificial intelligence (AI)-designed anti-prolactin receptor (PRLR) antibody, ABS-201. The funds will primarily support a global Phase II study for endometriosis by the end of 2026 and potential Phase III studies for male pattern hair loss in late 2027, leveraging positive early Phase I safety and tolerability data. The company believes ABS-201 could offer a durable treatment option for hair loss and potentially address other autoimmune and inflammatory diseases where prolactin plays a role.
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts
Absci Corporation (NASDAQ:ABSI) has received a consensus "Moderate Buy" rating from analysts, with eight out of nine recommending a buy and an average 12-month price target of $12.57. This positive sentiment follows promising interim Phase 1 data for its ABS-201 hair-loss drug and a successful $100 million underwritten offering, which included participation from Eli Lilly. While the share sale introduces some dilution risk, the company's stock has seen a new 52-week high and increased institutional investment, driven by these positive developments.
Guggenheim Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $15
Guggenheim has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained its price target at $15. This suggests continued confidence from the analyst firm in the company's future performance.
Absci Corporation Stock 12‑Month Price Target Raised to $12, Implies 19% Upside
Absci Corporation's average 12-month stock price target has been increased from $11.81 to $12.4 by analysts, implying an approximate 23% potential upside based on its closing price on June 24. The consensus rating for ABSI among 11 analysts remains "Buy," with 10 recommending a Buy and one a Hold.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci Corporation announced positive interim Phase 1 data from its HEADLINE™ trial of ABS-201, a novel antibody targeting the Prolactin Receptor (PRLR), for androgenetic alopecia. The study medication appeared well-tolerated with favorable safety data across all single ascending dose cohorts, and a half-life of at least 65 days supports potential for a less frequent dosing interval. Absci anticipates interim proof-of-concept data for AGA in the second half of 2026 and plans to initiate a Phase 2 trial for endometriosis later this year.
United States - Goodwin Guides Absci On Pricing Of $100 Million Underwritten Offering
Goodwin Procter LLP advised Absci Corporation on its recent underwritten offering, which successfully priced 13,495,277 shares of common stock at $7.41 per share, raising approximately $100 million. The biotech company, Absci, plans to utilize these proceeds primarily to advance ABS-201, its AI-designed anti-PRLR antibody program for androgenetic alopecia and endometriosis, as well as for general corporate purposes. Absci is focused on drug discovery using an Integrated Drug Creation™ platform that combines AI models with a synthetic biology data engine to design biologics.
Form 424B5 Absci Corp For: 24 June By Investing.com
This article announces the filing of Form 424B5 for Absci Corp, dated June 24. It appears to be a standard financial market update provided by Investing.com, likely detailing information related to a securities offering or other corporate event. The article includes a stock symbol reference for Absci Corp (ABSI) and its current performance.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11
Needham has reiterated its Buy rating for Absci Corp (ABSI.US) and increased its target price to $11. This decision reflects a positive outlook on the company's prospects.
Absci (ABSI) Stock Pops As Wall Street Hikes Price Targets
Absci (ABSI) stock has risen by 18.56% due to positive sentiment following its AI-driven biopharma advancements and bullish coverage from Wall Street analysts. Leerink, Guggenheim, and BTIG all initiated or reiterated "Buy" ratings and significantly raised price targets, highlighting the potential of ABSI's lead asset, ABS-201, in hair loss and endometriosis, and the company's AI-native drug discovery platform. Despite being a development-stage company with negative earnings, analysts project multi-billion-dollar sales if clinical trials prove successful, making it a high-volatility, catalyst-driven trade.
Absci (ABSI) Stock Rallies As Wall Street Boosts Targets
Absci (ABSI) stock has surged by 28.2% due to positive news regarding its AI-driven drug discovery efforts. Wall Street analysts have boosted price targets for ABSI, citing its AI-native platform and the significant potential of its lead asset, ABS-201, for which key proof-of-concept data is expected in the second half of the year. Despite the company's current negative profitability, the strong analyst sentiment and AI narrative are driving momentum trading in the stock.
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci (NASDAQ: ABSI) has raised $100 million through an equity offering to fund its AI-designed drug candidate, ABS-201, which targets androgenetic alopecia (hair loss) and endometriosis. The company announced positive interim Phase 1 trial results for ABS-201, showing a favorable safety and pharmacokinetic profile, and plans to advance to a Phase 2 trial for endometriosis later this year. Following these announcements, Absci's shares saw a significant increase in premarket trading.
Absci (ABSI) Surges 20% in Premarket Following $100M Financing Deal
Absci Corp (ABSI) saw a 20% premarket surge after securing $100 million in funding from Eli Lilly and private equity firms. This capital will primarily support the development of ABS-201 for androgenetic alopecia and endometriosis, as well as general corporate needs. Despite a moderate GF Score™ of 48/100 and strong financial strength, the company faces challenges in profitability and has a high valuation, indicating a complex investment opportunity for investors to monitor closely.
Absci Reports Positive Interim Phase 1 Data for ABS-201; Half-Life ≥65 Days Supports Biannual Dosing
Absci announced positive interim Phase 1 safety and pharmacokinetic data for ABS-201, showing it was well tolerated with no serious adverse events. The drug demonstrated an estimated half-life of at least 65 days, which supports biannual dosing with two or three injections over six months. The company has begun dosing participants in a multiple ascending dose study for androgenetic alopecia, expecting proof-of-concept data in H2 2026.
Absci raises $100M as Lilly joins investors backing AI drug program
Absci (Nasdaq: ABSI) announced the pricing of an underwritten public offering, raising approximately $100 million by selling 13,495,277 common shares at $7.41 per share. The proceeds will fund the advancement of ABS-201, an AI-designed anti-PRLR antibody program, for treating androgenetic alopecia and endometriosis, as well as general corporate purposes. Eli Lilly & Company and several leading institutional investors participated in the financing.
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Absci Corporation has announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at $7.41 per share, aiming to raise approximately $100 million. The proceeds will fund the advancement of ABS-201, an AI-designed anti-PRLR antibody program for androgenetic alopecia and endometriosis, as well as for general corporate purposes. The offering includes investment from Eli Lilly & Company and several leading financial institutions.
Absci rises after early-stage trial data for hair loss therapy and $100M stock offering
Absci (ABSI) shares rose significantly in premarket trading after the company released early-stage trial data for its hair loss therapy, ABS-201. Concurrently, Absci announced an underwritten stock offering aiming to raise approximately $100 million. The positive data readout and the stock offering collectively impacted the company's stock performance.
Guggenheim is Bullish on Absci Corporation (ABSI)
Guggenheim has increased its price target for Absci Corporation (ABSI) to $15 from $10, maintaining a “Buy” rating ahead of upcoming data for its AI-designed drug, ABS-201. Absci's CEO Sean McClain highlighted that ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, has significant sales potential and could represent a new mechanism of action. The company also announced a second preclinical antibody, ABS-202, for inflammation and immunology, expanding its pipeline.
Absci Corp stock hits 52-week high at 8.18 USD
Absci Corp (ABSI) stock has surged to a new 52-week high of $8.18, marking a 193.84% increase over the past year. This comes despite a significant revenue shortfall in Q1 2026, offset by slightly better-than-expected EPS. Analyst firms Guggenheim and BTIG have issued "Buy" ratings and price targets of $15 and $9, respectively, driven by optimism for the company's lead asset ABS-201 and its AI drug platform.
Absci Corp stock hits 52-week high at 8.18 USD
Absci Corp's stock has reached a new 52-week high of $8.18, driven by strong momentum and positive analyst ratings from Guggenheim and BTIG. This comes despite a significant revenue shortfall in Q1 2026, though the company's EPS slightly exceeded expectations. The optimism is largely due to the potential of its lead asset ABS-201 and its AI drug platform.
Absci Corp stock hits 52-week high at 8.18 USD By Investing.com
Absci Corp (ABSI) stock recently hit a 52-week high of $8.18, marking a 193.84% increase over the past year. Despite a significant revenue shortfall in Q1 2026, the company’s AI drug platform has garnered positive attention from analysts, with Guggenheim and BTIG initiating Buy ratings and setting price targets of $15 and $9 respectively. InvestingPro indicates the stock is currently overvalued, highlighting its strong momentum and high volatility.
Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery
Absci Corporation has initiated human trials for ABS-201, a generative AI-designed monoclonal antibody targeting androgenetic alopecia, reaching the clinical stage in approximately 24 months. The Phase 1/2a HEADLINE trial, which began in Australia in December 2025, will assess the drug's safety and efficacy in treating hair loss. This milestone represents a significant test for Absci’s AI-driven drug discovery platform, which aims to accelerate drug development timelines.
Absci Corp (ABSI) Institutional Confidence
Absci Corp (ABSI) has an institutional shareholding score of 7.00, placing it highly within the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.40%, a significant increase from the previous quarter. Catherine Wood is the largest institutional shareholder, holding 7.98 million shares, representing 8.84% of outstanding shares.
Absci Corp (ABSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Absci Corp (ABSI), but notes that relevant financial data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It indicates where such information would typically be presented once it becomes available. The page also displays current stock information and market cap for Absci Corp.
Leerink’s AI Pipeline Focus and Jones AI Day Spotlight Might Change The Case For Investing In Absci (ABSI)
Leerink initiated coverage on Absci Corporation, highlighting its AI-driven clinical pipeline, including lead candidate ABS-20 and pipeline asset ABS-201, while Absci's CEO participated in a Jones AI Day panel. This new visibility could influence the investment narrative, emphasizing Absci's platform and upcoming clinical data milestones in 2026 and 2027 for ABS-201. However, the core risk remains the uncertainty of early human data and the company's financial runway.
Leerink’s AI Pipeline Focus and Jones AI Day Spotlight Might Change The Case For Investing In Absci (ABSI)
Leerink recently initiated coverage on Absci Corporation (ABSI), highlighting its AI-native biologics pipeline, including lead candidate ABS-20 and ABS-201. Concurrently, Absci participated in a Jones AI Day panel discussing AI-enabled drug discovery, increasing the company's visibility. While upcoming clinical data for ABS-201 in 2026 and 2027 are crucial, the increased attention from capital markets and the AI drug discovery ecosystem could influence Absci's investment narrative, despite risks like ongoing losses and a limited cash runway.
Absci Corp (ABSI) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Absci Corp (ABSI), highlighting its current earnings forecast score of 8.36 and an average price target of $9.00 based on 11 analyst ratings, predominantly "Buy." It details expected revenue for the next quarter at $1.24M and projects an EPS of -$0.20. The report also includes a peer comparison in the Biotechnology & Medical Research industry.
Absci Corp stock hits 52-week high at 7.44 USD By Investing.com
Absci Corp (ABSI) stock reached a new 52-week high at $7.44, currently trading at $7.74 with a market capitalization of $1.06 billion, reflecting a 141.13% increase over the past year. Despite this growth, InvestingPro data suggests the stock might be overvalued relative to its Fair Value. The company recently reported Q1 2026 revenue of $215,000, significantly below expectations, though EPS marginally beat forecasts; however, analysts like Guggenheim and BTIG remain positive, setting price targets of $15 and $9 respectively, citing potential in ABS-201 and Absci's AI drug platform.
Guggenheim Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $15
Guggenheim analyst Vamil Divan has reiterated a "Buy" rating for Absci Corp (ABSI.US) and increased the target price from $10 to $15. Divan's past performance shows a 57.5% success rate and an average return of 10.8% over the last year, according to TipRanks data. This move indicates a positive outlook on the company's stock performance.
Leerink Starts Coverage on Absci Corporation (ABSI)
Leerink initiated coverage on Absci Corporation (NASDAQ:ABSI) with an Outperform rating and a $12 price target, citing its "AI-native, clinical-stage story" and an "18-month catalyst path." The company's lead asset, ABS-201, is in Phase 1/2 for androgenetic alopecia, with Phase 2 in endometriosis expected in Q4 2026. CEO Sean McClain stated that 2026 will be a "data-rich year" for the drug and target discovery firm.
Absci Corp stock hits 52-week high at 7.44 USD By Investing.com
Absci Corp's stock has reached a 52-week high of $7.44, currently trading at $7.74 with a market capitalization of $1.06 billion, demonstrating a 141.13% increase over the past year. Despite this strong performance, InvestingPro data suggests the stock may be overvalued relative to its Fair Value. Recent analyst updates from Guggenheim and BTIG, however, maintain Buy ratings and raised price targets, citing potential in the company's lead asset and AI drug platform, even after a disappointing Q1 2026 revenue report.
Absci Corp (ABSI) awards RSUs and stock options to director Szela
Absci Corp (ABSI) director Mary T. Szela was granted 8,400 Restricted Stock Units and 33,200 stock options with an exercise price of $7.34 per share. These equity awards will vest fully on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, provided her continuous service to the company. This disclosure was made in an amended Form 4 filing, correcting the previously reported amounts.
Absci Corp stock hits 52-week high at 7.44 USD
Absci Corp (ABSI) stock has reached a new 52-week high of $7.44, reflecting strong investor confidence and a 141.13% increase over the past year, with a current market capitalization of $1.06 billion. Despite this milestone, InvestingPro suggests the stock may be overvalued relative to its Fair Value. The company recently reported disappointing Q1 2026 revenue but saw analyst upgrades from Guggenheim and BTIG due to its AI drug platform and lead asset potential in the hair loss market.
